^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    SLAMF8 overexpression

    i
    Other names: SLAMF8, SLAM Family Member 8, BLAME, SBBI42, CD353, BCM-Like Membrane Protein, B Lymphocyte Activator Macrophage Expressed, B-Lymphocyte Activator Macrophage Expressed, CD353 Antigen
    Entrez ID:
    56833
    almost3years
    SLAMF8, a potential new immune checkpoint molecule, is associated with the prognosis of colorectal cancer. (PubMed, Transl Oncol)
    The mRNA expression level of SLAMF8 was positively correlated with the expression levels of multiple classic immune checkpoints and other SLAM family members. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis suggested that the pathways enriched in CRC tissues with high SLAMF8 expression were associated with the regulation of the tumor immune microenvironment.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    SLAMF8 (SLAM Family Member 8)
    |
    SLAMF8 overexpression
    over4years
    SLAMF8 expression predicts the efficacy of anti-PD1 immunotherapy in gastrointestinal cancers. (PubMed, Clin Transl Immunology)
    Exogenous overexpression of SLAMF8 in macrophages resulted in enrichment of positive regulation of multiple immune-related pathways. Higher SLAMF8 expression may predict better anti-PD1 immunotherapy efficacy in GI cancer.
    Clinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • SLAMF8 (SLAM Family Member 8)
    |
    CD8 expression • SLAMF8 overexpression